Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Declines By 15.3%

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 75,300 shares, a drop of 15.3% from the February 13th total of 88,900 shares. Currently, 11.0% of the company’s stock are sold short. Based on an average daily trading volume, of 49,500 shares, the short-interest ratio is presently 1.5 days.

Qualigen Therapeutics Price Performance

QLGN traded down $0.02 during mid-day trading on Thursday, reaching $3.10. 1,325 shares of the stock were exchanged, compared to its average volume of 99,184. The company has a 50 day moving average price of $3.50 and a two-hundred day moving average price of $5.17. Qualigen Therapeutics has a 1 year low of $2.96 and a 1 year high of $29.44.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.